{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:49:11Z","timestamp":1787064551114,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.vaccine.2013.09.034","type":"journal-article","created":{"date-parts":[[2013,10,6]],"date-time":"2013-10-06T05:45:35Z","timestamp":1381038335000},"page":"268-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of serogroup C and ACWY meningococcal vaccine programs: Projected impact on disease burden according to a stochastic two-strain dynamic model"],"prefix":"10.1016","volume":"33","author":[{"given":"David M.","family":"Vickers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Anonychuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"De Wals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Demarteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris T.","family":"Bauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.09.034_bib0005","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0010","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0015","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1073\/pnas.0400695101","article-title":"Diversity in pathogenicity can cause outbreaks of meningococcal disease","volume":"101","author":"Stollenwerk","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0020","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1286-4579(00)00356-7","article-title":"Epidemiology and pathogenesis of Neisseria meningiditis","volume":"2","author":"Tzeng","year":"2000","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0025","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0264-410X(00)00333-9","article-title":"Development of natural immunity to Neisseria meningitides","volume":"19","author":"Pollard","year":"2001","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2013.09.034_bib0030","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/INF.0b013e31819040e7","article-title":"The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada","volume":"28","author":"Bettinger","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1098\/rsif.2007.0236","article-title":"Vaccine-induced pathogen strain replacement: what are the mechanisms?","volume":"5","author":"Martcheva","year":"2008","journal-title":"J Roy Soc Interface"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0040","series-title":"Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. Canada Communicable Disease Report 35","author":"NACI","year":"2009"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/aje\/kwi160","article-title":"Dynamic models of meningococcal carriage, disease and the impact of serogroup C conjugate vaccination","volume":"162","author":"Trotter","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0050","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1016\/j.vaccine.2009.01.092","article-title":"On the relationship between meningococcal transmission dynamics and disease: remarks on humoral immunity","volume":"27","author":"Guzzetta","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2013.09.034_bib0055","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with out membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2013.09.034_bib0060","doi-asserted-by":"crossref","first-page":"e00163","DOI":"10.1128\/mBio.00163-13","article-title":"Conservation of meningococcal antigens in the genus Neisseria","volume":"4","author":"Muzzi","year":"2013","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0065","series-title":"Stochastic epidemic models and their statistical analysis","author":"Andersson","year":"2000"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0070","series-title":"Vital statistics","author":"Statistics_Canada","year":"2012"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0075","series-title":"Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998","first-page":"26","author":"PHAC","year":"2000"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0080","series-title":"Enhanced surveillance of invasive meningococcal disease in Canada, 1 January 1999 through 31 December 2001","first-page":"30","author":"PHAC","year":"2004"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0085","series-title":"Canadian Immunization Guide","author":"PHAC","year":"2006"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0090","volume":"32(8)","author":"PHAC","year":"2006"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0095","volume":"33(10)","author":"PHAC","year":"2007"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0100","volume":"3562(Suppl.)","author":"PHAC","year":"2010"},{"issue":"9","key":"10.1016\/j.vaccine.2013.09.034_bib0105","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1086\/378743","article-title":"Neisseria meningitidis carriage during an outbreak of Serogroup C disease","volume":"37","author":"Patrick","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0110","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/ije\/14.4.628","article-title":"Methods for estimating the duration of bacterial carriage","volume":"14","author":"DeWals","year":"1985","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0115","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0120","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus: development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.vaccine.2013.09.034_bib0125","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated post-licensure surveillance of meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlate of protection and modelling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vacc Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.09.034_bib0130","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1371\/journal.pmed.0050074","article-title":"Social contacts and mixing patterns relevant to the spread of infectious diseases","volume":"5","author":"Mossong","year":"2008","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2013.09.034_bib0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF03405553","article-title":"Meningococcal Serogroup C conjugate vaccination in Canada: how far have we progressed? How far do we have to go?","volume":"101","author":"White","year":"2010","journal-title":"Can J Public Health"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0140","series-title":"Enqu\u00eate sur la couverture vaccinale des enfants de 1 an et 2 ans au Qu\u00e9bec en 2010","author":"Boulianne","year":"2011"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2013.09.034_bib0145","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: the experience in England and Wales","volume":"27","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2013.09.034_bib0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxj006","article-title":"Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and diseases","volume":"28","author":"Dasbach","year":"2006","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.vaccine.2013.09.034_bib0155","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.vaccine.2011.10.067","article-title":"Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada","volume":"30","author":"Tully","year":"2012","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2013.09.034_bib0160","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1016\/j.vaccine.2010.05.056","article-title":"Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis","volume":"28","author":"van de Velde","year":"2010","journal-title":"Vaccine"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2013.09.034_bib0165","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.vaccine.2006.05.116","article-title":"Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes","volume":"24","author":"Garnett","year":"2006","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2013.09.034_bib0170","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.vaccine.2004.10.029","article-title":"An analytical framework for immunization programs in Canada","volume":"23","author":"Erickson","year":"2005","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:21:13Z","timestamp":1759400473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13012759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0264410X13012759"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of serogroup C and ACWY meningococcal vaccine programs: Projected impact on disease burden according to a stochastic two-strain dynamic model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}